Rates of blood borne viruses (BBVs) are high among people who inject drugs (PWID). Vaccination provides protection against hepatitis B virus (HBV). BBV testing is the first step to accessing treatment. Orange Guidelines encourage focus on ongoing and emerging risk. Aim to assess rates of HBV vaccination, BBV testing and engagement with appropriate treatment services for those testing positive within our service and to compare this with national rates. Retrospective re-audit of all patients in treatment with our service at time of data collection (total 248). Chart reviewed for whether BBV testing been offered and completed, the date of completion and results. Referral to or engagement with the appropriate service checked for BBV. We checked whether HBV vaccination was offered and completed. The data was collated, analysed, and presented at our addictions academic meeting. 97.98% were offered vaccination. 59.27% had partial completion of schedule. 99.2% had BBV testing offered. 93.5% had BBV testing performed. 65.3% was within the last 12 months. Of BBV results available, 52.1% were negative for all, 47.9% had previous HCV exposure, 27.4% had HCV active infection, 0.9% were HBV exposed and 2.7% had HIV infection. All patients infected with HIV were engaged with the appropriate service. For HCV exposed patients, 41% were undergoing or completed treatment. Among those with antiHCV, prevalence of HCV RNA was lower in the UAM survey 2019 (42%) compared with our service population (57%). Vaccination rates and communication with other services and access to HCV treatment were identified as areas for improvement.